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Trends in diagnosis and treatment for people with dementia 
in the UK from 2005 to 2015: a longitudinal retrospective 
cohort study
Katherine Donegan, Nick Fox, Nick Black, Gill Livingston, Sube Banerjee, Alistair Burns
Summary
Background The objectives of this study were to describe changes in the proportion of people diagnosed with dementia 
and the pharmacological treatments prescribed to them over a 10 year period from 2005 to 2015 at a time of UK policy 
strategies and prioritisation of dementia. We aimed to explore the potential impact of policy on dementia care.
Methods In this longitudinal retrospective cohort study, we included all patients registered at a Clinical Practice 
Research Datalink (CPRD) practice between July 1, 2005, and June 30, 2015, with a diagnosis of dementia defined 
using Read codes. The main outcomes were the number and proportion of acceptable patients, who met the CPRD 
threshold for data quality, in a GP practice defined by the CPRD as contributing up-to-standard data with a diagnosis 
of dementia and the number and proportion of these with a prescription for an antidementia or antipsychotic 
medication. We examined the prevalence of dementia diagnosis and prescribing by calendar quarter, and stratified by 
age, sex, and UK country (England, Scotland, Wales, or Northern Ireland). We investigated the use of antidementia 
drugs, alone and in combination, antipsychotics, antidepressants, anxiolytics, and hypnotics. The trend in the 
proportion of patients with a diagnosis of dementia, before and after the introduction of the UK National Dementia 
Strategy, was estimated using an interrupted time-series analysis.
Findings 8 966 224 patients were identified in the CPRD whose most recent registration period overlapped the study 
period. Of these, 128 249 (1·4%) had a diagnosis of dementia before the end of the study period. The proportion of 
people diagnosed with dementia in the UK doubled from 0·42% (19 635 of 4 640 290 participants) in 2005 to 0·82% 
(25 925 of 3 159 754 participants) in 2015 (χ² test for trend, p<0·0001), and the proportion of those who received 
antidementia medication increased from 15·0% (2942 of 19 635) to 36·3% (9406 of 25 925). The interrupted time-series 
analysis showed a significant acceleration in the rate of diagnosis of dementia after the introduction of the UK 
National Dementia Strategy (p<0·0001). There was a large reduction in antipsychotic drug prescription in dementia 
from 22·1% (4347 of 19 635) in 2005 to 11·4% (2943 of 25 925) by 2015.
Interpretation Over the 10 years studied, there is evidence of a sustained positive change in diagnosis rates of dementia 
and in the quality of drug treatment provided to those diagnosed. The prescription of antidementia drugs more than 
doubled and the prescription of potentially hazardous antipsychotics halved after the introduction of national 
dementia strategies. These data support the formulation and delivery of national policy to improve the quality of care 
for people with dementia.
Funding None.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
In 2014, 850 000 people in the UK were estimated to have 
dementia, supported by approximately 540 000 family 
carers.1 These numbers are set to rise markedly both in the 
developed and in the developing world as the population 
ages in the coming decades.2,3 Dementia causes irreversible 
and continuing decline in global intellectual, social, 
and physical functioning; behavioural and psychological 
disturbances are also common. The illness is a major 
challenge to health and social services. The current cost to 
the UK economy is estimated at £26 billion per year,1,4 and 
the effect on families is profound, with around 40% of 
family carers developing depression or anxiety,5,6 which 
might lead to the person with dementia entering a care 
home. Dementia has become a national priority within the 
UK. The Prime Minister’s 2012 and 2015 Challenges on 
Dementia identified aspects of particular importance: 
prevention, research, awareness, tackling stigma, and 
diagnosis with high quality post-diagnostic support.
A priority identified in 2009 in the National Dementia 
Strategy for England7 and confirmed in subsequent 
policy is the need to increase the rate of diagnosis of 
dementia. The National Dementia Strategy estimated 
that only a third of people with dementia ever received a 
diagnosis of dementia. An estimate for England based on 
routine data in 2011–12 suggested that 42% of the 
estimated number of people with dementia had been 
diagnosed.8 However, determining the national diagnosis 
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rate is complicated as there are difficulties in estimating 
both the number of people with a diagnosis of dementia 
and the actual number in the population with dementia.9 
In such calculations, the numerator depends on general 
practitioners reporting accurately in the annual Quality 
and Outcomes Framework the number of people 
registered with dementia in their care.10 The number 
registered has risen rapidly by 10% a year in England, 
from 232 000 in 2008–09 to 344 000 in 2013–14. The 
denominator is derived from a consensus view based on 
several surveys done between 1989 and 2011, but since 
March, 2015, the estimate has been based on the CFAS II 
study.11 Given these uncertainties, one report estimated 
that the diagnosis rate for England in 2012–13 could have 
been as low as 36% or as high as 54% and for 2013–14, 
their best estimate was 50% (344 000 of 686 000).12
Concomitant with improving diagnosis in dementia is 
the challenge of providing high quality support, care, 
and treatment. On the basis of available evidence, and 
as part of a comprehensive package of care, national 
guidelines recommend three acetylcholinesterase 
inhibitors—donepezil, galantamine, and rivastigmine—
for the management of mild to moderate Alzheimer’s 
disease and memantine for people with severe 
Alzheimer’s disease (or those with moderate Alzheimer’s 
disease who are intolerant of acetylcholinesterase 
inhibitors).13 The same guidelines, similarly to many 
international initiatives, discourage the routine use of 
medication for non-cognitive symptoms or challenging 
behaviour. In particular, antipsychotic medication 
should only be used in dementia when absolutely 
necessary and should be time limited and regularly 
reviewed. This is because antipsychotic medication is of 
limited efficacy,14 associated with an increased mortality 
and morbidity,15,16 and often can be successfully 
withdrawn.17 Indeed, only one antipsychotic, risperidone, 
is licensed for the treatment of dementia-related 
behavioural disturbances, and it is specifically for up to 
6 weeks treatment of persistent aggression in 
Alzheimer’s dementia unresponsive to non-
pharmacological approaches and where there is a risk of 
harm to the patient or others.
Information on secular trends in dementia diagnosis 
and its treatment is important to understand the effect of 
policies, clinical guidance, and the provision of treatments 
in dementia. Given the limitations of universal routine 
data collection in primary care in the UK, it can be helpful 
to make use of the established databases available, such as 
the Clinical Practice Research Datalink (CPRD).18 This 
initiative collects data for patient characteristics, diagnoses, 
investigations, prescriptions, and referrals to secondary 
care from over 670 participating practices (covering 
approximately 6·9% of the population of the UK).
We aimed to use CPRD data to describe changes in the 
proportion of patients diagnosed with dementia and 
associated drug treatments over time (specifically the use 
of antidementia drugs, alone and in combination; 
antipsychotic medications, excluding prochlorperazine 
which is prescribed for dizziness; antidepressants; 
anxiolytics; and hypnotics).
Methods
Study design and patients
In this longitudinal retrospective cohort study, we 
included all patients whose most recent active registration 
at a CPRD practice overlapped with the study period 
July 1, 2005, to June 30, 2015. We further identified all 
patients with a diagnosis of dementia before the end of 
the study period based on the definition used in the 
Quality and Outcomes Framework and defined using 
Read codes, the standard clinical terminology system 
used in general practice in the UK.10 Diagnoses were 
identified from the patient electronic record with no 
additional verification with the general practitioner.
Patients were eligible for inclusion in the analysis for 
a specific calendar quarter if they were registered for 
Research in context
Evidence before this study
No formal literature search was done. Articles were identified 
through searches of the authors’ own files. The National 
Dementia Policy in England over the past decade has been to 
increase the proportion of people with dementia receiving a 
diagnosis as a gateway to good management. This includes 
receiving appropriate medication. Systematic reviews of 
antipsychotics have shown these are often ineffective and 
cause substantial harm, whereas reviews of 
acetylcholinesterase inhibitors including from the Cochrane 
Collaboration have shown clinically significant benefit. To our 
knowledge, only one previous peer-reviewed study has 
examined the benefit of this policy and it did not examine 
more recent changes or prescriptions of antipsychotics, 
antidepressants, anxiolytics, or hypnotics.
Added value of this study
With use of the Clinical Practice Research Datalink, a 
representative database from UK primary care, there is evidence 
of a sustained increase in diagnosis rates of dementia and in the 
quality of drug treatment provided in those diagnosed between 
2005 and 2015. The policies of increasing the use of antidementia 
drugs (more than doubled) and avoiding potentially hazardous 
antipsychotics (halved) have proved successful.
Implications of all the available evidence
This study, together with previous data, provides evidence that 
national policy can change medical practice, despite a systematic 
review of earlier trials of interventions to increase diagnosis rate, 
which found them to be unsuccessful. Furthermore, it shows that 
improvements can be made in the quality of care for the 
increasing number of vulnerable individuals with dementia.
For more on the Clinical Practice 
Research Datalink see 
http://www.cprd.co.uk/intro.asp
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the whole of that quarter in a practice assessed to be 
up-to-standard in terms of data quality by the CPRD 
research team. The CPRD has broad National Research 
Ethics Service Committee ethics approval for purely 
observational research such as this study. No individual 
patient consent was required.
Outcomes
The main outcomes of interest were a diagnosis of 
dementia and prescriptions for an antidementia drug, an 
antipsychotic (excluding prochloperazine), an anxiolytic, a 
hypnotic, or an antidepressant. Combination therapy for 
antidementia drugs was defined as having a prescription 
for a acetylcholinesterase inhibitor and memantine on 
the same day. Where dates of diagnoses or prescriptions 
were missing, these event records were excluded. All code 
lists are available from the study authors on request. 
Statistical analysis
The number and proportion of patients with a diagnosis 
of dementia was examined by calendar quarter, and 
stratified by age, sex, and UK country (England, Scotland, 
Wales, and Northern Ireland). The trend in the proportion 
of patients with a diagnosis of dementia was estimated 
using interrupted time-series analysis19 using a binomial 
generalised linear model with first order lagged residuals 
and seasonality accounted for by adjusting for calendar 
quarter. The intervention was defined as the launch of the 
National Dementia Strategy in 2009. 
We analysed three measures of antidementia drug 
prescription by calendar quarter: in the total study 
population, in people with a diagnosis of dementia, and 
in those specifically with a diagnosis of Alzheimer’s 
disease. The number and proportion of patients with a 
prescription for an antidementia drug was examined by 
calendar quarter, and stratified by the drug substance as 
well as age, sex, and UK country. The use of combination 
antidementia therapy was also considered in patients 
with a diagnosis of dementia. 
In patients with a diagnosis of dementia, the number 
and proportion of patients with a prescription for an 
antipsychotic (overall and atypical vs typical antipsychotics), 
an anxiolytic, a hypnotic, or an antidepressant was also 
examined by calendar quarter. All analyses were done with 
Stata, version 11.2. 
Role of the funding source
There was no funding source for this study.
Results
8 966 224 patients were identified in the CPRD whose 
most recent registration period overlapped the study 
period. Of these, 128 249 (1·4%) had a diagnosis of 
dementia before the end of the study period, two-thirds 
(84 254 [66%]) of whom were female.
Across the UK, the proportion of people with a 
dementia diagnosis increased significantly from 0·42% 
(19 635 of 4 640 290) to 0·82% (25 925 of 3 159 754; χ² test 
for trend, p<0·0001) during the study period with similar 
proportional increases seen in both men and women. 
An increase was seen in all areas of the UK. In England, 
the proportion of people with a diagnosis of dementia 
increased from 0·41% (14 936 of 3 651 585) in 
July–September, 2005, to 0·74% (21 462 of 2 916 792) in 
January–March, 2014 (figure 1). The proportion was 
consistently higher in Scotland and Northern Ireland 
than in England and Wales. However, data for the second 
quarter of 2015 show that the proportion in England 
(18 145 [0·82%] of 2 225 185) is now closer to that seen in 
Scotland (3991 [0·88%] of 455 034) and Northern Ireland 
(1336 [0·90%] of 148 043). A recent increase in diagnoses 
in Wales has also been observed. Diagnosis recording 
rates increased as expected with age (figure 1). An 
increase in the diagnosis rate over time was consistently 
seen regardless of age although the proportional increase 
in the rate of diagnosis was higher in older patients, with 
Figure 1: Proportion of CPRD population diagnosed with dementia in the UK by region (A) and age (B) 
between July, 2005, and June, 2015
Dates are month/year. Dotted line indicates launch of National Dementia Strategy (February, 2009). CPRD=Clinical 
Practice Research Datalink.
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the prevalence of diagnosis in those aged 90 years or 
older almost doubling.
With the use of estimates from the interrupted time 
series, we can see that before the introduction of the 
National Dementia Strategy, the proportion of patients 
with a diagnosis of dementia was increasing (quarter on 
quarter odds ratio [OR] 1·014, 95% CI 1·012–1·015, 
p<0·0001). After introduction of the programme, there 
was no evidence of a stepped change in the rate of 
diagnosis of dementia (OR 0·996, 95% CI 0·988–1·004, 
p=0·37), but a significant acceleration in the trend in the 
proportion of patients with a diagnoses was observed 
(Wald test, p<0·0001). The quarter on quarter change in 
the overall diagnosis rate is shown in figure 2, which also 
suggests an acceleration in recorded diagnoses in recent 
years compared with previous years.
43 718 (0·49%) people in the total population were 
prescribed an antidementia drug during the study with 
the rate of current prescribing increasing approximately 
four-fold over the 10 year study period (from 3752 [0·08%] 
of 4 640 290 in 2005 to 10 069 [0·32%] of 3 159 754 in 2015), 
largely accounted for by an increase in the use of 
donepezil (2524 [0·05%] in 2005 to 5948 [0·19%] in 2015) 
and memantine (220 [<0·01%] in 2005 to 2572 [0·08%] 
in 2015; data not shown). Prescribing was more common 
in women and in people over the age of 80 years. The rate 
of prescribing has increased across the UK and is 
consistently highest in Northern Ireland.
There were 37 246 patients with a diagnosis of 
dementia and a prescription for an antidementia drug 
(figure 3). This means that approximately 6500 people 
(15% of the total) were prescribed an antidementia drug 
without a diagnosis of dementia clearly recorded in their 
primary care record. Over the 10 year study period, the 
rate of prescribing of antidementia drugs in patients 
with a diagnosis of dementia has risen from 2942 (15·0%) 
of 19 635 in 2005 to 9406 (36·3%) of 25 925 in 2015. The 
most commonly prescribed antidementia drug across 
the whole period was donepezil. A large increase in the 
prevalence of use of memantine has been seen since the 
start of 2012. The difference between the number of 
identified patients with dementia with a prescription for 
an antidementia drug and the number of patients with a 
prescription regardless of diagnosis implies that a small 
proportion of patients are receiving a prescription for an 
antidementia drug without a documented and logistically 
extractable dementia diagnosis.
Patients with a diagnosis of Alzheimer’s disease 
(46 047 [36%] of 128 249) were more likely to be prescribed 
an antidementia drug than those with other diagnoses 
(figure 4). By 2015, about 55% (6075 of 10 980) of those 
with Alzheimer’s disease were prescribed an anti-
dementia drug. Prescribing levels of donepezil and 
memantine increased from 17·5% (1225 of 6994) in 2005 
to 35·7% (3925 of 10 980) in 2015 and from 1·8% 
(126 of 6994) in 2005 to 13·2% (1453 of 10 980) in 2015, 
respectively, but remained low for galantamine and 
rivastigmine.
Since 2010, concomitant use of a acetylcholinesterase 
inhibitor and memantine for the treatment of dementia 
has increased from 96 (0·4%) of 26 066 of those with 
dementia at the start of 2010 to 435 (1·7%) of 25 925 by 
quarter 2 of 2015.
The prescription of antipsychotic drugs in patients 
with dementia has significantly decreased from 
4347 (22·1%) of 19 635 in 2005 to 2943 (11·4%) of 
25 925 by 2015 (figure 5). There was a greater reduction 
in prescribing of the older (typical) medications (from 
1837 [9·4%] to 488 [1·9%]) than the atypical ones, which 
increased from 2667 (13·6%) of 19 635 in mid-2005 
to 3931 (16·8%) 23 424 in late 2007 before decreasing 
again to 2502 (9·7%) of 25 925. 
There have also been changes in the prescribing rates 
of hypnotics and antidepressants in patients with 
Figure 2: Quarterly changes in the proportion of patients in the CPRD with a diagnosis of dementia
Dotted line indicates launch of National Dementia Strategy (February, 2009). Dates are month/year. CPRD=Clinical Practice Research Datalink.
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dementia but not in anxiolytics (figure 6). Although the 
use of hypnotics decreased from 2805 (14·3%) 
of 19 635 to 2475 (9·5%) of 25 925, the use of anti-
depressants increased from 5494 (28·0%) to 9498 (36·6%).
Discussion
This large sample of people with dementia drawn from 
general practices that participate in the CPRD shows that 
the number and proportion of patients diagnosed with 
dementia in the UK rose steadily between 2005 and 2015, 
reflecting both the ageing population and greater clinical 
awareness, in line with national policies and guidelines. 
Nevertheless, many individuals never receive a diagnosis 
of dementia7,8 and might therefore be denied the possibility, 
for either themselves or their family, of making choices or 
gaining appropriate help. There are differences across the 
four countries of the UK (with a higher prevalence of 
diagnoses in Scotland and Northern Ireland than in 
England and Wales), but the trends are common to all.
Our study is in line with, and extends the findings of, 
another study considering the effect of the National 
Dementia Strategy,8 which tested the validity of the 
Quality and Outcomes Framework data in dementia and 
found it to be highly correlated with prescription of 
acetylcholinesterase inhibitors. The proportion of people 
with a diagnosis of dementia increased each quarter 
before and after the National Dementia Strategy was 
launched in 2009. This study shows the numbers 
continuing to increase until the end of 2015.
The proportion of people with a diagnosis of dementia 
who received drugs for Alzheimer’s disease has increased 
by a factor of more than two in the study period. This might 
partly be because of the change in National Institute 
for Health and Care Excellence (NICE) guidelines in 
Figure 3: Proportion of patients with a diagnosis for dementia prescribed an antidementia drug
Dates are month/year. CPRD=Clinical Practice Research Datalink.
Figure 4: Proportion of patients with a diagnosis for Alzheimer’s disease prescribed an antidementia drug
Dates are month/year. CPRD=Clinical Practice Research Datalink.
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August, 2009, so that those with mild dementia were 
allowed prescription of acetyl cholin ester ase inhibitors. 
However, the use of Read codes probably underestimates 
the proportion of patients with Alzheimer’s disease, which 
is the most common cause of dementia and accounts for 
60–70% of cases,1 as non-specific Read codes are often 
used in primary care for dementia.18 Even so, only 
around 50% of those who were recorded as having a 
diagnosis of Alzheimer’s disease were prescribed 
acetylcholinesterase inhibitors or memantine. Although 
some patients and their families will not want or be able to 
tolerate these drugs, the figures suggest they are still 
under-prescribed, despite evidence showing that 
continued use both improves cognitive outcomes and 
delays care home admission.20
There is a large increase in the proportion of people with 
Alzheimer’s disease who receive both a acetyl cholinesterase 
inhibitor and memantine over the study period. This 
proportion remained largely steady until 2011 but has 
increased greatly since then, without a change in policy or 
new evidence to suggest that this is cost-effective. 
Individuals with a prescription for both drugs in the 
same period might, however, have been switching from 
one to another because of side-effects or increasing 
dementia severity.
Conversely, a proportion of patients are receiving 
medication for dementia but are not recorded as having a 
diagnosis of dementia. Some of these individuals without 
a diagnosis of dementia might be receiving 
acetylcholinesterase inhibitors for mild cognitive 
impairment. In view of the evidence that 
acetyl cholinesterase inhibitors do not help those with 
mild cognitive impairment and might be harmful, this 
would be of concern.21 However, many of these individuals 
Figure 5: Proportion of patients with a diagnosis for dementia prescribed an antipsychotic drug
Dates are month/year. CPRD=Clinical Practice Research Datalink.
Figure 6: Proportion of patients with a diagnosis for dementia prescribed an anxiolytic, hypnotic, or antidepressant
Dates are month/year. CPRD=Clinical Practice Research Datalink.
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might have a diagnosis of dementia or Alzheimer’s 
disease made in secondary care but not recorded in the 
general practitioner database, despite policy initiatives. 
Hence, the true number of people with a diagnosis and 
who have received care in a memory clinic and other 
dementia pathways might be higher than Quality and 
Outcomes Framework figures.18
There have been concerns about the harms associated 
with the use of antipsychotics in dementia that pre-date 
the period covered by this report. There has been, and 
continues to be, a policy that there should be a reduction 
in the prescription of antipsychotic medications which, 
aside from risperidone, are not licensed for the treatment 
of dementia and indeed we observed a downward trend in 
the use of antipsychotics in this study. It is appropriate 
that the prescribing rate of typical antipsychotics, which 
are more harmful, has decreased more than that of 
atypical antipsychotics and is evidence of an under-
standing of the greater risks of older antipsychotics. 
There are differences across the four countries of the UK, 
but the trends in the use of antipsychotics are common to 
all. Further data have emerged immediately before and 
after the study period, and there have been a number of 
initiatives and guidelines aimed at reducing inappropriate 
use. Particularly important for UK prescribing was the 
guidance from the Committee on Safety of Medicines 
issued in 2004 that drew attention to the increased risk of 
cerebrovascular adverse events and greater mortality and 
the Time for Change14 report in 2009 that quantified the 
excess 1800 deaths attributable to the use of these drugs 
in dementia in the UK at that time.
As those who have a pre-existing psychosis are not 
protected from dementia and some individuals with 
dementia have psychotic and other neuropsychiatric 
symptoms that cause them great distress, there cannot 
be a zero level of prescription of these drugs in dementia. 
This is supported by a recent trial finding17 that reduction 
of antipsychotics after review in care homes led to 
increasing neuropsychiatric symptoms and that it is 
important that there are other management strategies to 
take the place of antipsychotics.22,23 One of the possible 
strategies that professionals might have used is the 
substitution of other psychotropic medications for 
antipsychotics. To our knowledge, this is the first study 
to address whether an increase in prescribing of 
antidepressants has occurred and this seems possible, 
despite evidence that they are ineffective and potentially 
harmful in depression associated with dementia.24
The strengths of this study include the large sample size 
and the fact that in the UK, most dementia diagnosis and 
treatment is made by the NHS hence the stability of the 
methods through a longitudinal study across a decade. 
Although CPRD is a valuable resource, it does have 
limitations as it includes only a sample of practices which 
might not be wholly representative of national clinical 
practice, diagnoses are dependent on Read codes and have 
not been validated, and the database only holds data for 
prescriptions with no information about whether the 
medication has been dispensed or adhered to. As only 
the primary care data has been used, diagnoses and 
prescriptions made in specialised care and not recorded in 
the primary care record will be missing. This leads to the 
already discussed difficulties in estimating the number of 
people in the population with dementia with and without 
a diagnosis. Finally, this observational study cannot 
confidently attribute the changes or trends observed to 
any specific initiative. For example, communications and 
recommendations from the Medicines and Healthcare 
products Regulatory Agency and other organisations such 
as NICE will also have contributed to changes in practice. 
The interrupted time series shown should be interpreted 
with caution for this reason, as well as because the 
implementation of the National Dementia Strategy will 
have occurred over some time.
These limitations in inference notwithstanding, it is 
encouraging that there are increasing diagnosis rates and 
decreasing use of antipsychotic drugs in dementia and that 
the national quality improvement initiatives taken in the 
UK appear to be associated, at least temporally, with 
improvements in the key indicators presented here. The 
value of decreasing the use of antipsychotic medication is 
driven by the avoidance of the morbidity and mortality 
associated with their prescription to people with dementia. 
The estimates of these harms are derived from multiple 
randomised controlled trials.14 In terms of the value of 
increasing diagnosis rates, there is no evidence from 
randomised controlled trials that receiving a diagnosis 
(compared with having dementia but not being given that 
diagnosis) is associated with improved quality of life and 
some have raised the possible harms of early diagnosis.25 
However, the evidence from observational studies is 
encouraging. Statistically significant improvements in 
health-related quality of life (HRQoL) in the first 6 months 
after diagnosis were reported in the evaluation of the 
Croydon Memory Service Model26 and more recently in a 
national evaluation of Memory Assessment Services.27 
Weighing the available evidence for diagnosis in dementia 
in a series of systematic reviews, the 2011 World Alzheimer 
Report concluded that there was value for people with 
dementia themselves, their carers, and society as a whole 
in clinical and economic terms28 on the basis of 
optimisation of medical management; the relief gained 
from better understanding of symptoms; maximising 
decision-making autonomy; access to services; risk 
reduction; planning for the future; improving clinical 
outcomes; avoiding or reducing future costs; and diagnosis 
as a human right.
There is still some way to go, and further exploration of 
prescribing practices (eg, the duration of treatment) 
might be of value in informing future direction, but 
these data present evidence of a sustained change for the 
better in dementia diagnosis and treatment in the UK 
and support the development and delivery of national 
policies to improve care for people with dementia.
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